PBYI Live signaler | Maksimer profitt med Getagraph.com

KJøP 115908 min ago

@ $7.35

Utstedt: 14 feb 2024 @ 21:31

Avkastning: -33.88%

Forrige signal: feb 13 - 21:35

Forrige signal: Selg

Avkastning: 18.17 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
Dagens volum	388 031
Gjennomsnittsvolum	585 132
Markedsverdi	234.29M
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $-0.220 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	10.80
ATR14	$0.00900 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.70
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

Volum Korrelasjon

Lang: 0.14 (neutral)

Kort: -0.68 (moderate negative)

Signal:(32.798) Neutral

Puma Biotechnology Inc Korrelasjon

10 Mest positive korrelasjoner
FAT	0.831
OHAA	0.828
ISEM	0.815

10 Mest negative korrelasjoner
RMRM	-0.839

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Puma Biotechnology Inc Korrelasjon - Valuta/Råvare

0.50
( neutral )

0.48
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.45
( neutral )

Puma Biotechnology Inc Økonomi

Annual	2023
Omsetning:	$235.64M
Bruttogevinst:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
Omsetning:	$235.64M
Bruttogevinst:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
Omsetning:	$228.00M
Bruttogevinst:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
Omsetning:	$253.16M
Bruttogevinst:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.